Page 110 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 110
Chapter 5
Figure 4. Tumor uptake of 89Zr-antiCD20 (37 MBq74inj). Bland-Altman plots for two count reduced images (H1 and H2) for SUVpeak at D3 (a) and D6 (b). Solid lines represent mean percentage difference, dashed lines represent upper and lower LoA.
Reliability analysis
The ICCs for normal tissue and tumor uptake of Zr-89-mAbs are shown in Table 2 and Supplemental Table 4. For the manually delineated organs, ICCs > 0.9 were obtained at all time points for 89Zr-antiCD20 mAb (37 MBq74inj and 18 MBq74inj). For 89Zr-antiCD20 mAb (37 MBq74inj), blood pool and bone marrow ICCs were lower, with values as low as 0.74 and with wider 95% confidence intervals than for the manually delineated organs.
For tumor uptake of 89Zr-mAbs, ICCs of > 0.9 were obtained in all datasets, despite RC of 40%. Similar tumor ICCs of 0.9 were obtained for 89Zr-antiCD20 mAb (18 MBq74inj), 89Zr-89Zr-antiEGFR mAb (18 MBq37MBq), 89Zr-antiCD44 mAb (18MBq37MBq). Increase in the range of tumor uptake between tumor lesions over time for 89Zr-antiCD20 (37 MBq74inj) (Fig. 5), resulted in a higher ICC at D6. This trend was not observed for 89Zr-antiEGFR (18 MBq37inj).
108
